Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Haematologica|May 7, 2011
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELAOlivier Fitoussi, Karim Belhadj, Nicolas Mounier, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2023
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, et al.
Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsJudith Trotman, Marion Fournier, Thierry Lamy, et al.
Blood|December 11, 2012
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemiaMarlène Pasquet, Christine Bellanné-Chantelot, Suzanne Tavitian, et al.
Haematologica|January 21, 2018
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphomaEric Van Den Neste, Marc André, Thomas Gastinne, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Pageof 9